Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6118-6128

  Gebhard, Claudia ^a   Schwarzfischer, Lucia ^a   Pham, Thu Hang ^a   Schilling, Elmar ^a   Klug, Maja ^a   Andreesen, Reinhard ^a   Rehli, Michael ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; METHYL CPG BINDING PROTEIN; RECOMBINANT ANTIBODY;

ARTICLE; BLAST CELL; CPG ISLAND; DISEASE MARKER; DNA DETERMINATION; DNA FINGERPRINTING; DNA METHYLATION; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN BINDING; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ACUTE DISEASE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOPRECIPITATION; LEUKEMIA, MYELOID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; U937 CELLS;

EID: 33745700202     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0376     Document Type: Article

References (40)

1. Costello JF, Plass C. Methylation matters. J Med Genet 2001;38:285-303.
2. Esteller M, Fraga MF, Paz MF, et al. Cancer epigenetics and methylation. Science 2002;297:1807-8.
3. Ng HH, Bird A. DNA methylation and chromatin modification. Curr Opin Genet Dev 1999;9:158-63.
4. Razin A. CpG methylation, chromatin structure, and gene silencing-a three-way connection. EMBO J 1998;17:4905-8.
5. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6:597-610.
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
7. Momparler RL. Cancer epigenetics. Oncogene 2003;22:6479-83.
8. Plass C. Cancer epigenomics. Hum Mol Genet 2002;11:2479-88.
9. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-8.
10. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
11. Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 2005;205:172-80.
12. Kalebic T. Epigenetic changes: potential therapeutic targets. Ann N Y Acad Sci 2003;983:278-85.
13. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003;4:351-8.
14. Dahl C, Guldberg P. DNA methylation analysis techniques. Biogerontology 2003;4:233-50.
15. Krause SW, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis JD, Andreesen R. Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 1996;60:540-5.
16. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-31.
17. Haehnel V, Schwarzfischer L, Fenton MJ, Rehli M. Transcriptional regulation of the human toll-like receptor 2 gene in monocytes and macrophages. J Immunol 2002;168:5629-37.
18. Cross SH, Charlton JA, Nan X, Bird AP. Purification of CpG islands using a methylated DNA binding column. Nat Genet 1994;6:236-44.
19. Zeschnigk M, Schmitz B, Dittrich B, Buiting K, Horsthemke B, Doerfler W. Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method. Hum Mol Genet 1997;6:387-95.
20. Chim CS, Wong AS, Kwong YL. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias. Ann Hematol 2003;82:738-42.
21. Dodge JE, List AF, Futscher BW. Selective variegated methylation of the p15 CpG island in acute myeloid leukemia. Int J Cancer 1998;78:561-7.
22. Dodge JE, Munson C, List AF. KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. Leuk Res 2001;25:917-25.
23. Issa JP, Zehnbauer BA, Civin CI, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 1996;56:973-7.
24. Paz MF, Wei S, Cigudosa JC, et al. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 2003;12:2209-19.
25. Douglas DB, Akiyama Y, Carraway H, et al. Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2α expression during progression of breast cancer. Cancer Res 2004;64:1611-20.
26. Schwab J, Illges H. Regulation of CD21 expression by DNA methylation and histone deacetylation. Int Immunol 2001;13:705-10.
27. Sato K, Tamura G, Tsuchiya T, et al. Frequent loss of expression without sequence mutations of the DCC gene in primary gastric cancer. Br J Cancer 2001;85:199-203.
28. Jones PA, Wolkowicz MJ, Rideout WM III, et al. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc Natl Acad Sci U S A 1990;87:6117-21.
29. Yuan BZ, Durkin ME, Popescu NC. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet 2003;140:113-7.
30. Choi MC, Jong HS, Kim TY, et al. AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene 2004;23:7095-103.
31. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005;37:853-62.
32. Costello JF, Smiraglia DJ, Plass C. Restriction landmark genome scanning. Methods 2002;27:144-9.
33. Smith RJ, Dean W, Konfortova G, Kelsey G. Identification of novel imprinted genes in a genome-wide screen for maternal methylation. Genome Res 2003;13:558-69.
34. Yan PS, Chen CM, Shi H, et al. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 2001;61:8375-80.
35. Brock GJ, Huang TH, Chen CM, Johnson KJ. A novel technique for the identification of CpG islands exhibiting altered methylation patterns (ICEAMP). Nucleic Acids Res 2001;29:E123.
36. Shiraishi M, Chuu YH, Sekiya T. Isolation of DNA fragments associated with methylated CpG islands in human adenocarcinomas of the lung using a methylated DNA binding column and denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A 1999;96:2913-8.
37. Klose RJ, Sarraf SA, Schmiedeberg L, McDermott SM, Stancheva I, Bird AP. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 2005;19:667-78.
38. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 2003;31:1765-74.
39. Rush LJ, Dai Z, Smiraglia DJ, et al. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood 2001;97:3226-33.
40. Kelly LM, Englmeier U, Lafon I, Sieweke MH, Graf T. MafB is an inducer of monocytic differentiation. EMBO J 2000;19:1987-97.